Back

Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin

27 May 2018 (15:45 - 15:51)
Organised by:
Congress Presentation Part of: Moderated Poster session 3 - Novel treatment Cardiotoxicity of Drugs and Other Therapies HFA Premium Access Heart Failure 2018

6 More presentations in this session

Presentation thumbnail
What proportion of patients with HFrEF might be candidates for Sacubitril-Valsartan?
Doctor T. O connor (Dublin 9, IE)
Abstract Slides
Presentation thumbnail
Heart failure patients with reduced left ventricular ejection fraction, who reached 100% target dose of beta-blockers in randomized and observational studies
Mrs M. Oyanguren Artola (Bilbao, ES)
Abstract Slides
Presentation thumbnail
Metabolic response to exercise training in heart failure with preserved ejection fraction
Doctor M. Bahls (Greifswald, DE)
Abstract
Presentation thumbnail
Adherence to ESC guidelines after hospital admission for heart failure in 22500 Dutch patients: 2001-2015
Mrs W. Kruik-Kolloffel (Almelo, NL)
Abstract Slides
Presentation thumbnail
Cardiovascular outcomes with the incretin-based therapies GLP-1 agonists and DPP-4 inhibitors in type 2 diabetes participants with and without heart failure
Doctor S. Zheng (London, GB)
Abstract Slides

Access the full session

Session thumbnail
Moderated Poster session 3 - Novel treatment

The Event

Event poster

Heart Failure 2018

27 May 2018 15:45 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources